What is sermorelin?
Sermorelin is the grandfather of the GHRH peptide family in clinical use — FDA-approved in 1997 for pediatric growth hormone deficiency, with a clinical track record that predates CJC-1295, tesamorelin, and most of the compounds in this guide by a decade or more. The manufacturer voluntarily discontinued it in 2008 for commercial reasons — not safety — and it's been available exclusively through compounding pharmacies ever since, where it's become one of the most prescribed anti-aging peptides in the U.S.
Sermorelin is the first 29 amino acids of GHRH — the shortest GHRH fragment that retains full GHRH receptor binding and biological activity. It works identically to the GHRH portion of CJC-1295 (no-DAC) but has a shorter half-life (~11 minutes vs. ~30 minutes for Mod GRF 1-29). This means daily injection is required, but the pulsatile GH release profile closely mimics natural GHRH signaling — the most physiological of all GHRH analogs.
For biohackers choosing between GHRH analogs, sermorelin occupies a specific niche: the most conservative, best-characterized, longest-track-record GHRH option. Physicians who prescribe anti-aging peptides often start patients on sermorelin specifically because of its extensive clinical history. CJC-1295 and tesamorelin may be pharmacologically superior in specific ways, but sermorelin's decades of medical use data provide a level of clinical confidence that newer analogs lack.
How it works
GHRH Receptor Activation
Sermorelin binds GHRH receptors (GHRHR) on anterior pituitary somatotroph cells, activating adenylyl cyclase → cAMP → PKA → GH gene transcription and GH secretion. The mechanism is identical to natural GHRH and to the GHRH component of CJC-1295. The difference is duration: sermorelin's 11-minute half-life produces a brief, acute GH pulse rather than sustained stimulation.
Pulsatile GH Release — Most Physiological Profile
Of all the GHRH analogs, sermorelin produces the most physiologically similar GH release pattern to natural GHRH — brief pulses that clear within minutes, followed by normal somatostatin regulation. This close mimicry of natural GH pulsatility is why many clinicians prefer it: the GH release is amplified but natural in character, preserving receptor sensitivity and normal feedback regulation better than longer-acting analogs.
Gradual IGF-1 Restoration
With daily use over months, sermorelin gradually restores more youthful GH pulsatility, and IGF-1 rises correspondingly. The rise is slower than CJC-1295 DAC or GH secretagogue combinations — IGF-1 increases over weeks rather than days. This gradual elevation is associated with fewer side effects and less risk of supraphysiologic IGF-1, which is appropriate for anti-aging protocols that prioritize long-term safety.
What the research shows
Effects of single nightly injections of GHRH(1-29) in healthy elderly men
Vittone J, Blackman MR, Busby-Whitehead J et al.
11 healthy elderly men (64–76) self-injected 2 mg GHRH(1-29) — the sermorelin sequence — nightly for 6 weeks. It raised nocturnal GH release and peak amplitude, but GH pulse frequency, IGF-1, IGFBP-3, and body composition (DEXA muscle and fat) were all unchanged. An honest early signal: short-term GHRH lifts GH output without yet moving IGF-1 or body composition, so the anti-aging payoff needs longer or different dosing.
View on PubMed →Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF
An editorial making the mechanistic case for sermorelin over recombinant hGH in age-related GH decline: because it stimulates the patient's own pituitary, output stays under normal somatostatin negative feedback (overdose is nearly impossible), release is episodic and physiologic rather than 'square-wave', it avoids tachyphylaxis, and it up-regulates pituitary GH gene transcription to preserve pituitary reserve — plus off-label use is not federally restricted the way rhGH is. The conceptual foundation for sermorelin in longevity medicine.
View on PubMed →Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children
Thorner M, Rochiccioli P, Colle M et al.
The pediatric GHRH(1-29)/sermorelin trial (Geref International Study Group): 110 GH-deficient children given 30 µg/kg nightly subcutaneously grew faster — mean height velocity rose from ~4.1 to ~8.0 cm/yr at 6 months, 74% responded, and it was well tolerated with no adverse biochemical changes or IGF-1 overshoot. Human evidence underpinning sermorelin's pediatric clinical track record.
View on PubMed →What the community reports
Sermorelin's community skews older and more medically supervised than most peptide communities — many users access it through anti-aging clinics and functional medicine practices. This produces a more conservative, longer-protocol-oriented community where effects are tracked over months.
Common misconceptions
"Sermorelin is outdated — CJC-1295 replaced it."
CJC-1295 (no-DAC) has pharmacokinetic advantages: longer half-life, less frequent dosing, higher GH peaks. But sermorelin's clinical track record — decades of medical use data, FDA approval history, extensive pediatric and adult safety data — provides clinical confidence that newer analogs lack. For conservative, medically supervised protocols, sermorelin's history is a feature.
"Sermorelin is no longer available."
The brand Geref was discontinued in 2008 by the manufacturer. Sermorelin itself is widely available through compounding pharmacies with a prescription — it's one of the most commonly compounded anti-aging peptides in the U.S.
"Results should be visible in the first 2 weeks."
Sermorelin's gradual, physiological GH elevation produces visible results over months, not weeks. Sleep improvement may come early. Body composition changes typically become apparent at months 3–6. Users who expect the rapid response of GHRP-2 + CJC-1295 combinations will be disappointed by sermorelin's timeline.
COMPARE
CJC-1295 — longer half-life (~30 min), higher GH peaks, less frequent dosing. More potent but less clinical history. Tesamorelin — FDA-approved GHRH analog with specific visceral fat evidence. Ipamorelin — the clean ghrelin-receptor stack partner for dual-receptor GH optimization.
Open PepperLedger to track your sermorelin protocol →
Free to join. No credit card. Ask the Researcher about your sermorelin protocol once you're in.
Free to join · No credit card · 23-day Pro trial included
Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.
- ClinicalTrials.gov · completed · NCT02553603Growth hormone releasing hormone (sermorelin-class) on cognition in MCI